Our study revealed that knockdown of SEC14L3 significantly enhances the sensitivity of ccRCC cells to sunitinib, with the most pronounced therapeutic effect observed when SEC14L3 knockdown is combined with sunitinib treatment. This evidence concerns the gene SEC14L3 and nonpapillary renal cell carcinoma.